The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Tepylute is indicated for the treatment of adenocarcinoma of the breast or ovary . It is now supplied as a multiple-dose vial containing 100mg of thiotepa, in addition to the previously approved ...

Polyethylene glycol 400 0.4%, propylene glycol 0.3%; oph soln; contains aminomethylpropanol, polyquaternium-1, sorbitol. Soln—15mL, 30mL, 40mL; Preservative-free vials (0.01oz)—28; Ultra Soln ...

Tepylute does contain a high concentration of polyethylene glycol (PEG) 400. The PEG 400 load from concomitant medications should be taken into consideration when prescribing Tepylute. Both vial ...